Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Ernexa Therapeutics Inc.

Get SEC filing alerts via email and in your feed for Ernexa Therapeutics Inc.

ERNA

Ernexa Therapeutics Inc.

About Ernexa Therapeutics Inc.

Eterna Therapeutics Inc. is a preclinical-stage biotech company developing allogeneic mesenchymal stem cell (iMSC) therapies for cancer and autoimmune diseases. Its core focus is on off-the-shelf cellular treatments leveraging iPSC-derived stem cells to target solid tumors and inflammation. The company emphasizes innovative gene editing, nucleic acid technologies, and strategic partnerships to advance its pipeline and intellectual property portfolio.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Ernexa Therapeutics Inc.

1
1
Ernexa Therapeutics Inc. Ernexa Therapeutics Reports $5.5 Million Net Loss in Q1 2026, Improves Cash Position

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Ernexa Therapeutics Inc. Ernexa Therapeutics Reports $14.1 Million Net Loss for Fiscal Year 2025, Seeks Additional Capital

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Ernexa Therapeutics Inc. Ernexa Therapeutics Reports $1.2 Million Net Loss in Q3 2025, Revenue Declines to Zero

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Ernexa Therapeutics Inc. Ernexa Therapeutics Reports $3.1 Million Net Loss in Q2 2025, No Revenue Generated

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Ernexa Therapeutics Inc. Eterna Therapeutics Reports Zero Revenue and $8.2 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Ernexa Therapeutics Inc. Eterna Therapeutics Reports Revenue Increase to $582,000 but Faces $44.5 Million Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Ernexa Therapeutics Inc. Eterna Therapeutics Reports Significant Financial Decline, Doubts Ability to Continue as Going Concern

Via official filing (AI summary) | over 1 year ago | 0 comments